Market Overview

Morgan Stanley Downgrades Cytokinetics to Equal-Weight, Lowers Price Target to $9


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for CYTK

Sep 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Sep 2018Morgan StanleyAssumesEqual-Weight
Aug 2018Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for CYTK
View the Latest Analyst Ratings

Posted-In: News Downgrades Analyst Ratings


Related Articles (CYTK)

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

A Peek Into The Markets: US Stock Futures Mixed Ahead Of Fed Decision